You searched for "AMD"
The disease burden of AMD
1 December 2015
| Efrosini Papagiannuli
|
Retina / Uvea / Vitreous
In this multi-centre, prospective, observational, time and motion study the authors assessed the time burden of managing wet AMD for doctors, staff, patients and caregivers in the USA. The study spanned the period from March 2011 to August 2012, and...
Multimodal imaging in wet AMD
1 April 2019
| Saruban Pasu
|
Retina / Uvea / Vitreous
This novel study set out to determine grader agreement levels of various retinal imaging techniques, commonly used in the diagnosis of wet age-related macular degeneration (AMD). Images from 52 eyes were by examined by two different observers. All images were...
Macular pigment in relatives of AMD patients
3 April 2024
| Kurt Spiteri Cornish
|
Retina / Uvea / Vitreous
Blue light causes photo-oxidative retinal injury and macular pigment (MP), with lutein, zeaxanthin and mesozeaxanthin as the main components, as a filter that protects the macula from this damage. Previous studies indicated that low levels of macular pigment optical density...
Computerised visual acuity measurements in AMD
1 December 2015
| Nana Theodorou
|
Retina / Uvea / Vitreous
The aims of this study were to investigate whether half-letter width spacing in COMPlog algorithms had an adverse effect on agreement in patients with AMD with the ETDRS chart. Fifty adult participants with AMD took part with a median age...
Features of AMD treatment non-responders
This is a retrospective consecutive case series of 365 eyes with age-related macular degeneration (AMD) who had three monthly intravitreal aflibercept treatments for at least 12 months. Responders were defined as complete resolution of exudation, intraretinal oedema, subretinal fluid, pigment...Detection of antiranibizumab antibodies in exudative AMD
1 December 2014
| Sofia Rokerya
|
Retina / Uvea / Vitreous
In this study the authors aimed to detect immune response to ranibizumab treatment in wet age-related macular degeneration (AMD). An ELISA was employed to quantify the anti-ranibizumab titre which was compared against the control anti-abciximab titre. Titres of anti-ranibizumab antibodies...
Outcomes of ‘treat and extend’ for neovascular AMD
1 August 2015
| Brian Ang
|
Retina / Uvea / Vitreous
The authors report on 24-month outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy using a ‘treat and extend’ regime for treatment-naïve neovascular age-related macular degeneration (nAMD). Data for this study was collected from the Fight Retinal Blindness observational registry based...
AMD and visceral fat and pro-inflammatory factors
1 December 2015
| Bheemanagouda Patil
|
Retina / Uvea / Vitreous
|
AMD, body mass index, pro-inflammatory factors, visceral fat
Several large studies have shown a positive relationship between age-related macular degeneration (ARMD) and high body mass index. The waist-hip ratio is also associated with development of early AMD. Visceral fat has a pro-inflammatory effect, which means it has an...
Visual acuity after cataract surgery in AMD patients
1 October 2014
| Brian Ang
|
Cataract and Refractive
The data from this study are obtained from the Age-Related Eye Disease Study (AREDS) 2 and analysed to evaluate if cataract surgery benefits patients with concurrent age-related macular degeneration (AMD). The AREDS 2 was a five year, prospective, multi-centre randomised...
Is an increased homocysteine level associated with greater risk of AMD?
1 June 2015
| Jonathan CP Roos
|
Retina / Uvea / Vitreous
|
Age-related macular degeneration, Women's Health Study, homocysteine, prospective cohort, risk factor
Basic research studies have implicated homocysteine in causing vascular endothelial dysfunction and inflammation, and this has been borne out in large observational studies which suggested that elevated homocysteine is associated with increased risk of cardiovascular disease. In order to determine...
The long-term effects of AREDS on AMD progression
1 December 2013
| Brian Ang
|
Retina / Uvea / Vitreous
The Age-Related Eye Disease Study (AREDS) was an 11-centre, double-masked, clinical trial that in 2001 found a high-dose of antioxidant vitamins plus zinc was effective in protecting against progression of age-related macular degeneration (AMD) in patients with moderate to high...
Genetic profiling for personalised healthcare solutions in AMD – an update
1 August 2015
| Rod McNeil
|
Retina / Uvea / Vitreous
Age-related macular degeneration (AMD) is a multifactorial condition influenced by genetics and lifestyle factors (Table 1). This article outlines several recent advances in AMD genetics, as well as evolving therapeutic concepts and established practical measures for the treatment and /...